Nvidia's CEO Says America Can't Win at AI Without Selling to China

Nvidia reported record quarterly sales, though its outlook is significantly impacted by ongoing geopolitical challenges in the China market, where U.S. export curbs have halted sales of its H20 AI chip and the Chinese government has discouraged its use. Despite a potential 15% revenue-sharing agreement to resume sales, Nvidia excluded China H20 revenue from its current quarter forecast, prompting analyst concerns. CEO Jensen Huang asserts that accessing this estimated $50 billion market is crucial for U.S. AI competitiveness, not just Nvidia's growth, as the company actively seeks licenses for continued sales.

Analysis

Nvidia reported record quarterly sales, but this strong performance is materially overshadowed by significant geopolitical headwinds impacting its China operations. U.S. export curbs have halted sales of its H20 AI chip, prompting the company to exclude this revenue stream from its current-quarter forecast, which analysts noted was consequently a "hair light of the latest whispers." This uncertainty persists despite a potential 15% revenue-sharing agreement with the U.S. administration that is still being negotiated. The challenge is twofold, as the Chinese government has also reportedly asked local firms to avoid Nvidia's chips over security concerns. CEO Jensen Huang frames access to the Chinese market—an opportunity he estimates at $50 billion this year alone—as critical for U.S. AI competitiveness. CFO Colette Kress quantified the immediate potential upside, suggesting H20 shipments could generate $2 billion to $5 billion in quarterly revenue if the regulatory issues are resolved, while the company continues to lobby for licenses for more advanced products like its Blackwell chip.

Key Decisions for Investors

• Investors should closely monitor developments in U.S.-China trade policy, as any progress on the revenue-sharing agreement or new sales licenses represents a significant near-term catalyst that is not currently priced into guidance.
• The stock's valuation should be weighed against the binary risk of regulatory outcomes; while core business is strong, a prolonged impasse or further restrictions in China could cap upside potential and introduce volatility.
• Consider the dual-sided risk from both U.S. export controls and Chinese government actions, as a negative shift on either side could materially impact the company's ability to access what it estimates to be a $50 billion market opportunity.